Precision medicine for gastrointestinal cancers

New Horizons for Precision Medicine in Biliary Tract Cancers.

Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-prognosis and low-incidence cancers, although the incidence of intrahepatic cholangiocarcinoma is rising. A minority of patients present with resectable disease but relapse rates are high; benefit from adjuvant capecitabine chemotherapy has been demonstrated. Cisplatin/gemcitabine combination chemotherapy...

precision medicine for endocrinology

Precision Medicine for Childhood Cancers: Role of Epigenetics in Childhood Cancers

The prospect of having a child diagnosed with a cancer is a heart-wrenching experience and one in which subjects the child to painful and longterm consequences. Given the recent explosion of scientific understanding of human carcinogenesis, which involves both genetic and environmental factors playing a role in the development of those cancers, new concepts of “Precision Medicine”, “Personalize...

Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine

Pediatric cancers differ from adult tumors, especially by their very low mutational rate. Therefore, their etiology could be explained in part by other oncogenic mechanisms such as chromosomal rearrangements, supporting the possible implication of fusion genes in the development of pediatric cancers. Fusion genes result from chromosomal rearrangements leading to the juxtaposition of two genes. ...

Precision Chemistry for Precision Medicine

During the 2015 State of the Union address, President Obama unveiled plans for a $215 million Precision Medicine Initiative. The details of this plan were laid out by past and present directors of the National Institutes of Health, Harold Varmus and Francis Collins, in a commentary in the New England Journal of Medicine. While the announcement stood as a public statement of support for funding,...